Clinical Trial

Shanghai Eye Study for Adults

Study acronym: SESA
Recruiting
View on ClinicalTrials.gov →
Summary
Blindness and visual impairment severely impact the visual health and life quality of people, particularly the 2.566 million senior citizens aged at 65 and above in Shanghai. The main reason is uncorrected refractive error, of which, 62.1% can be solved through refractive correction. For this reason, the uncorrected refractive errors of 154,000 senior citizens in Shanghai can be taken as a priority among the public health issues to prevent blindness. Now, with the aim to reduce the prevalence rate of blindness and visual impairment, it is planned to establish a public health service mechanism in terms of refractive error screening and correction for the elderly by relying on Shanghai's three-level (city-district-community) eye diseases prevention network, using proper refractive correction technology, and moving related services forward to communities in order to screen, identity, and correct blindness and visual impairment caused by refractive errors as early as possible.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2018-02-27; most recent amendment 2022-05-17.
Trial Details
NCT Number NCT03455478
Lead Sponsor Shanghai Eye Disease Prevention and Treatment Center
Collaborators: Brien Holden Vision
Conditions Blindness,Visual Impairment, Refractive Error, Cataract, High Myopia, Aging
Enrollment 1,000,000 participants
Start Date 2016-01-01
Primary Completion 2019-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2022-05-24